Sterility Testing Market Size, Share, Market Trends, Business Revenue Statistics, Growth Prospective and Forecast 2023-2028

The Global Sterility Testing Market in terms of revenue was estimated to be worth $1.1 billion in 2023 and is poised to reach $1.9 billion in 2028, growing at a CAGR of 10.5% from 2023 to 2028. Factors responsible for the growth in the market are mainly the rising expansion of pharmaceutical & biopharmaceutical production capacities, increasing development of novel biopharmaceutical products, and rising investments in life science research. However, the growing adoption of single-use technology is a major factor restraining the market growth.

Download PDF Brochure:

Browse in-depth TOC on “Sterility Testing Market”

178 – Tables

35 – Figures

198 – Pages

Sterility Testing Market Dynamics

Drivers: Rising expansion of pharmaceutical & biopharmaceutical production capacities

In pharmaceutical and biopharmaceutical industries, sterility testing is conducted at all manufacturing stages to minimize the risk of product contamination. Subsequently, the growth of this end-use industry in the coming years will considerably boost the utilization of sterility testing.

The production capacity expansion of pharmaceuticals and biopharmaceuticals worldwide will augment the demand for sterility testing products and services. Sterility testing is mandatory during the production process of pharmaceuticals and biopharmaceuticals. Therefore, the rising production capacities of pharmaceutical & biopharmaceutical companies will drive the adoption of additional kits, reagents, and instruments for sterility tests.

For instance:

In 2022, Novartis (Switzerland) invested USD 300 million to bolster the capacity and capabilities for next-generation bio-therapeutics across Switzerland, Slovenia, and Austria.

In 2022, Eli Lilly and Company (US) invested USD 1.5 billion to establish two new manufacturing facilities: Concord, NC, and Limerick, Ireland. Of the total investment, the company aims to invest USD 500 million, specifically in Limerick, to create a new biologics active ingredients site.

Inquiry Before Buying @

Restraints: Growing adoption of single-use technology

Single-use technology substitutes the stainless-steel and hard-piped configurations used in aseptic processing and sterile manufacturing. Gamma-irradiated pre-assembled process systems are used under single-use technology. Such technology is used for aseptic filling as well as upstream & downstream processing. The main benefit of SUT is that time and money are not invested in labor-intensive and expensive cleaning, sterilization validation tests, or their recurring revalidation. Moreover, it eliminates system cleaning and sterilization requirement between batches. Adopting such technologies will hamper the demand for sterility testing products and services.

However, the chances of human error will continue, even if closed systems and single-use technology are used more frequently. Personnel continues to be the principal source of contamination for pharmaceutical & biopharmaceutical formulations that cannot be terminally sterilized. Thus, a thorough training program is essential. When adhering to GMP and quality standards, operator comprehension is a crucial factor.

Opportunities: Emerging markets

Emerging markets such as Brazil, India, and China are expected to present significant opportunities for the growth of the market. This can mainly be attributed to increased R&D funding for research in these countries. For instance, China & current healthcare expenditure (% of GDP) went from 5.1% in 2017 to 5.4% in 2019. Similarly, for India, the healthcare expenditure rose from 2.9% in 2017 to 3.0% in 2019, while for Brazil, it was 9.5% in 2017 and increased to 9.6% in 2019. (Source: World Bank)

Moreover, CDMOs and CROs based in emerging markets offer cost-efficient development and manufacturing services to pharma & biotech companies. Sterility testing is a mandatory step in pharmaceutical drug discovery & development. Therefore, the growing production capacities of CROs and CDMOs in emerging nations will augment the demand for sterility testing products and services. A few examples of such capacity expansions are as follows:

  • In August 2022, Samsung Biologics announced plans to build a second biopharmaceutical campus, named Bio Campus II, at Songdo, Incheon, South Korea
  • In July 2022, Wuxi Biologics announced a USD 1.4 billion investment for expanding its research, development, and large-scale drug substance and drug product manufacturing capacity and capabilities in Singapore.

The kits & reagents segment accounted for the largest share of the product & service segment in 2022

On the basis of product & service, the sterility testing market is segmented into kits & reagents, instruments, and services. In 2022, the kits & reagents segment accounted for the largest market share in sterility testing. Kits & reagents are widely used in the pharmaceutical and biotechnology industries as it is easy to use. Moreover, the long shelf life of these products is contributing to their rising adoption in academic institutions and contract research organizations.

 By test-type segment, membrane filtration accounted for the largest market share in 2022

Based on the test type, the sterility testing market is divided into membrane filtration, direct inoculation, and other tests. The membrane filtration segment accounted for the biggest share of the sterility testing market in 2022. Factors such as the growing demand for sterility testing of liquid dose formulations and the utility of such tests in samples containing preservatives and bacteriostatic & fungistatic compounds will boost segmental growth.

In 2022, the Asia region accounted as the fastest-growing region in the market

In 2022, the Asia region accounted for the fastest-growing region of the sterility testing market. Factors responsible for the growth of this region include the rising trend of outsourcing pharmaceutical activities to CROs and CDMOs coupled with growing demand from emerging markets such as China and India.Moreover, growing public and private investments in pharmaceutical and biopharmaceutical R&D activities in the region will also propel the growth of Asian sterility testing market over the forecast period.

Key Market Player

Prominent players operating in the biomarkers market are Charles River Laboratories, Inc. (US), Merck KGaA (Germany), bioMérieux SA (France), SGS SA (Switzerland), WuXi AppTec (China), Nelson Laboratories, LLC (US), Pacific BioLabs (US), Sartorius AG (Germany), Thermo Fisher Scientific Inc. (US), Samsung Biologics (South Korea). The study includes an in-depth competitive analysis of these key players in the modular data center market with their company profiles, recent developments, and key market strategies. The players in this market have embraced different strategies to expand their global presence and increase their market shares. New product launches and enhancements, partnerships, acquisitions, and collaborations have been the most dominating strategies adopted by the major players.

View detailed Table of Content here@

North America dominated the Sterility Testing Market in 2020

North America accounted for the largest share of the Sterility Testing Market in 2020, followed by Europe and Asia Pacific. The rising awareness of the benefits of functional foods in improving skin health, is responsible for the large share of North America in the Sterility Testing Market.

Mr. Aashish Mehra
MarketsandMarkets™ INC
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Visit Our Website:

About MarketsandMarkets™

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are moulded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit MarketsandMarkets™ or follow us on Twitter, LinkedIn and Facebook.